An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) with PT and PT only in Fibromyalgia, sponsored by Kathleen Sluka. Completed at 6 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Kathleen Sluka · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 29th largest by enrollment of the 320 interventional ones that give a count, is one of 19 that started in 2021, is one of 167 with no phase, and was the 284th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 19 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 459 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
Kathleen Sluka is the lead sponsor of 3 studies on the registry; none are open to participants now.
Kathleen Sluka has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06066853Spaulding Rehabilitation HospitalMDMA-assisted Therapy for Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if addition of Transcutaneous Electrical Nerve Stimulation (TENS) to routine physical therapy improves movement-evoked pain in patients with fibromyalgia (FM).
The study will also determine if addition of TENS to routine physical therapy (PT) improves disease activity and symptoms, increases adherence to physical therapy, increases the likelihood of meeting patient specific functional goals, and reduces medication use.
This study is a pragmatic clinical trial in outpatient PT practices utilizing cluster randomization by healthcare system and facility size. Sites will be randomized to enroll all eligible and consented participants with FM to TENS with PT, or PT only (no TENS). We are identifying 25-35 clinics across 6 healthcare systems in both rural and urban settings. We will enroll 450 patients that self report a clinician diagnosis of FM. At each site, TENS (or no TENS) will be applied during each visit along with individualized PT treatment specified by the physical therapist. Participants randomized to TENS intervention sites will receive TENS units and electrodes at baseline to be applied to the cervical and lumbar regions. Participants will take the units home and bring the units back to their PT clinic visits with instructions for use at home while active and during their exercises. The physical therapist at each clinic will complete routine documentation of treatment. In addition to the primary and secondary outcomes, Electronic Health Record data variables will be collected as exploratory outcomes. Variables including adherence to treatment will be extracted from each site's Electronic Health Record. Patient-reported assessments will be obtained from the participant's at home the day of their second PT visit (Baseline) and at 30, 60 (primary outcome), 90, and 180 days following enrollment. The primary and secondary outcome assessments will be comparing TENS and no TENS groups in terms of changes from baseline to 60 days.
Participants will be identified after they are referred for PT for treatment of primary fibromyalgia (FM) or chronic pain (pain lasting more than three months). At their first (intake) physical therapy visit, they will be provided information about the study that can be accessed on paper or on-line. They will perform an electronic screening form on the first visit if interested in participating. Participants will provide e-consent after eligibility is confirmed at the initial PT visit. At the second PT visit after e-consent is signed, participants will be provided instructions on logging onto REDCap for data capture and accessing the case report forms. Participants enrolled at a TENS site will then be instructed in use of TENS and the TENS unit with electrodes will be provided. Those participants enrolled at a no TENS site will skip the instruction in use of TENS but will then receive instructions along with the TENS units at day 65. Participants will be instructed to capture all baseline assessments at home before their next PT visit before and following their first TENS treatment (or no TENS) at home (day 1). At 30, 60, 90, and 180 days following enrollment, participants will complete the same assessments at home including pain ratings at rest and with movement along with questionnaires. The primary and secondary outcome assessments will be comparing TENS and no TENS groups in terms of changes from baseline to 60 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to TENS use including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.
Device: Transcutaneous Electrical Nerve Stimulation (TENS) with PT
The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.
Other: PT only
Use of TENS units along with routine PT therapy
Routine PT therapy only
Change in Movement-evoked Pain During the Sit and Stand Test
Numeric rating scale of -10 to 10 for change in movement-evoked pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in the Resting Pain Score
Numeric rating scale of -10 to 10 for change in resting pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in Pain Interference (BPI)
Numeric rating scale of -10 to 10 for change in pain interference. Change score was defined as pain scores at Day 60 (measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale) minus Day 1(measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale). Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in FM Disease Activity (FIQR)
The Revised Fibromyalgia Impact Questionnaire (FIQR; 0-100) is a 21-item, disease-specific patient-reported outcome measure that assesses function, overall impact, and symptoms of fibromyalgia. Change score (-100, 100) was defined as FIQR at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in Resting Fatigue
The severity of fatigue is measured with a 0 to 10 scale where 0 is no fatigue and 10 is worst fatigue imaginable. Change score is on a numeric rating scale of -10 to 10 for change resting fatigue pain and was defined as pain scores at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in Movement-evoked Fatigue
Fatigue during a five times sit and stand test is measured with a 0 to 10 numeric rating scale with 0 as no fatigue and 10 as the worst fatigue imaginable. Change score was defined as movement fatigue scores at Day 60 minus Day 1 resulting in a numeric rating scale of -10 to 10 for change movement-evoked fatigue. Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in Multidimensional Assessment of Fatigue (MAF)
MAF (1-50) is composed of 16 items measuring fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue, and impact on various activities of daily living. Change score was defined as MAF at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in Rapid Assessment of Physical Activity (RAPA) Aerobic
RAPA Aerobic (0-5 Low to High Scale) is composed of 5 items evaluating current level of physical activity. Change score was defined as RAPA Aerobic at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Change in Rapid Assessment of Physical Activity (RAPA) Strength and Flexibility
RAPA Strength and Flexibility (0-4, Low to High Scale) is composed of 4 items evaluating current level of physical activity. Change score was defined as RAPA Strength and Flexibility at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Patient Global Impression of Change (PGIC) (Improved, No Change, Worse)
Evaluates overall health status as perceived by the patient in a seven-point single-item scale ranging from 'very much worse' to 'very much improved'
Time frame: Day 60 +/- 5 days Home
36 Sites from 6 health care systems were screened. Participants were enrolled after completion of electronic informed consent between January 22, 2021, and September 31, 2024, with final data collected in March 2025. On PT visit 1, patients were assessed for eligibility with an electronic screening survey (REDCap). A total of 958 participants were screened, 459 participants enrolled, and 384 completed baseline data collection (modified intention to treat \[mITT\]).
| Milestone | TENS With PT | No TENS With PT |
|---|---|---|
| Started | 230 | 229 |
| Completed | 230 | 229 |
| Not completed | 0 | 0 |
| Milestone | TENS With PT | No TENS With PT |
|---|---|---|
| Started | 191 | 193 |
| Completed | 191 | 193 |
| Not completed | 0 | 0 |
| Milestone | TENS With PT | No TENS With PT |
|---|---|---|
| Started | 171 | 173 |
| Completed | 171 | 173 |
| Not completed | 0 | 0 |
Numeric rating scale of -10 to 10 for change in movement-evoked pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Movement-evoked Pain During the Sit and Stand Test | -1 (-1.4 to -0.7) | 0 (-0.3 to 0.3) |
Numeric rating scale of -10 to 10 for change in resting pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in the Resting Pain Score | -1 (-1.3 to -0.7) | -0.1 (-0.4 to 0.2) |
Numeric rating scale of -10 to 10 for change in pain interference. Change score was defined as pain scores at Day 60 (measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale) minus Day 1(measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale). Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Pain Interference (BPI) | -0.9 (-1.2 to -0.6) | -0.3 (-0.5 to -0.0) |
The Revised Fibromyalgia Impact Questionnaire (FIQR; 0-100) is a 21-item, disease-specific patient-reported outcome measure that assesses function, overall impact, and symptoms of fibromyalgia. Change score (-100, 100) was defined as FIQR at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in FM Disease Activity (FIQR) | -7.3 (-9.4 to -5.2) | -2.9 (-4.7 to -1.0) |
The severity of fatigue is measured with a 0 to 10 scale where 0 is no fatigue and 10 is worst fatigue imaginable. Change score is on a numeric rating scale of -10 to 10 for change resting fatigue pain and was defined as pain scores at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Resting Fatigue | -0.8 (-1.2 to -0.5) | -0.1 (-0.4 to 0.2) |
Fatigue during a five times sit and stand test is measured with a 0 to 10 numeric rating scale with 0 as no fatigue and 10 as the worst fatigue imaginable. Change score was defined as movement fatigue scores at Day 60 minus Day 1 resulting in a numeric rating scale of -10 to 10 for change movement-evoked fatigue. Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Movement-evoked Fatigue | -1.1 (-1.5 to -0.7) | -0.0 (-0.3 to 0.3) |
MAF (1-50) is composed of 16 items measuring fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue, and impact on various activities of daily living. Change score was defined as MAF at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Multidimensional Assessment of Fatigue (MAF) | -3.2 (-4.6 to -1.8) | -0.9 (-2.1 to 0.2) |
RAPA Aerobic (0-5 Low to High Scale) is composed of 5 items evaluating current level of physical activity. Change score was defined as RAPA Aerobic at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Rapid Assessment of Physical Activity (RAPA) Aerobic | 0.1 (-0.1 to 0.3) | 0.2 (0 to 0.4) |
RAPA Strength and Flexibility (0-4, Low to High Scale) is composed of 4 items evaluating current level of physical activity. Change score was defined as RAPA Strength and Flexibility at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.
| units | TENS With PT | No TENS With PT |
|---|---|---|
| Change in Rapid Assessment of Physical Activity (RAPA) Strength and Flexibility | 0.3 (0.1 to 0.4) | 0.4 (0.2 to 0.6) |
Evaluates overall health status as perceived by the patient in a seven-point single-item scale ranging from 'very much worse' to 'very much improved'
| Participants | TENS With PT | No TENS With PT |
|---|---|---|
| Improved | 120 | 86 |
| No Change | 32 | 58 |
| Worse | 14 | 26 |
Collected over "From Day 1 to Day 180 homework assessments for "TENS With PT" and "No TENS With PT" Arms/Groups; from Day 60 to 6-month follow-up for "Participants in No TENS With PT that started TENS with PT at Day 60" Arm/Group". Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TENS With PT (Day 1 - 180) | 0/179 (0%) | 0/179 (0%) | 71/179 (39.7%) |
| No TENS With PT (Day 1 - 60) | 0/179 (0%) | 0/179 (0%) | — |
| No TENS With PT (Day 60 - 180) | 0/179 (0%) | 0/179 (0%) | 38/179 (21.2%) |
| Event | TENS With PT (Day 1 - 180) | No TENS With PT (Day 1 - 60) | No TENS With PT (Day 60 - 180) |
|---|---|---|---|
| OtherProduct Issues | 48/179 | — | 24/179 |
| Skin irritation with electrodesSkin and subcutaneous tissue disorders | 17/179 | — | 7/179 |
| Itchiness with TENSSkin and subcutaneous tissue disorders | 16/179 | — | 6/179 |
| Pain with TENSNervous system disorders | 15/179 | — | 12/179 |
| Anxiety with TENSPsychiatric disorders | 11/179 | — | 4/179 |
| Nausea with TENSGastrointestinal disorders | 3/179 | — | 1/179 |
These represent the number of participants from our modified intention to treat population (i.e. who completed day 1 homework assessment)
| Age, Continuous(Years) | TENS With PT | No TENS With PT | Total |
|---|---|---|---|
| Mean | 52.6 ± 15.5 | 53.9 ± 14.8 | 53.2 ± 15.2 |
| Sex/Gender, Customized(Participants) | TENS With PT | No TENS With PT | Total |
|---|---|---|---|
| Female | 175 | 176 | 351 |
| Unknown/Prefer not to answer/Missing | 2 | 5 | 7 |
| Male | 14 | 12 | 26 |
| Race (NIH/OMB)(Participants) | TENS With PT | No TENS With PT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 17 | 15 | 32 |
| White | 156 | 159 | 315 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 11 | 11 | 22 |
| Ethnicity (NIH/OMB)(Participants) | TENS With PT | No TENS With PT | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 19 | 26 |
| Not Hispanic or Latino | 170 | 156 | 326 |
| Unknown or Not Reported | 14 | 18 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The current study is expected to generate patient-reported outcomes for individuals with fibromyalgia across a broad spectrum of domains, pain, fatigue, function, psychological factors, and quality of life. We will also collect some data from the electronic health record about number of physical therapy visits, Current Protocol Terminology (CPT) codes for treatments, and the patient-specific functional scale. In addition, we will have TENS usage data downloaded from the TENS devices that will show the number of minutes of TENS use and the number of 30 minute sessions completed. Data will be collected prior to the intervention (baseline data) and 30, 60, 90 and 180 days after enrollment.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Analysis datasets will be made available at the time of publication of the primary manuscript. Complete datasets and accompanying resources will be deposited to the designated NIH Helping to End Addiction Long-term initiative (HEAL) data repository after the completion of the primary aim manuscript.
Access criteria: In accordance with NIH Collaboratory policies, we will prepare the primary analysis datasets (at a minimum) for submission to the Collaboratory Coordinating Center. In accordance with International Committee of Medical Journal Editors (ICMJE) policies, we will prepare the primary analysis datasets for review and reproducibility by peer-reviewed journals. We will prepare the final datasets and accompanying resource documents for final deposit to the designated NIH HEAL data repository. Publications will be made available to the public using open access publishing, so they become available immediately to the public. All publications will be accessible through PubMED, google scholar, and available to the public through open access.
Ran from Jan 2021 to primary completion in Mar 2025, 49 months.
Results were first posted in Nov 2026, 1 year 7 months after primary completion.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 49 months is above that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.